NexGard Spectra® is a prescription only medicine. This site is provided as an information service for veterinary professionals working in the UK. Please tick ‘I’m a veterinary professional’ to confirm that you are a veterinary professional working in the UK (e.g. veterinary surgeon, veterinary nurse or veterinary student).
NEXT-LEVEL PROTECTION:
ONE AND DONE
Parasite protection couldn’t be easier. One monthly tasty chew controls these key parasites*:
Also licensed to treat ear mites† and can be used in breeding, pregnant and lactating bitches‡
Find out more
NexGard SPECTRA® protects against all these key parasites in a single chew
Activity against key dog parasites§
| NexGard Spectra® | Advocate® | CredelioTM | Simparica TrioTM | Bravecto® TriUNO | |
|---|---|---|---|---|---|
| Palatable | ✓ | Spot on |  | |  |
| Licensed for pregnancy/lactation | ✓ | |  | | |
| Can be given on empty stomach†† | ✓ | Spot on | | ✓ | |
| Fleas | ✓ | ✓ | ✓ | ✓ | ✓ |
| Ticks | ✓ | | ✓ | ✓ | ✓ |
| Mites including ear mites | ✓ | ✓ |  | | |
| Roundworm | ✓ | ✓ | ✓ | ✓ | ✓ |
| Lungworm | ✓ | ✓ | ✓ | ✓ | ✓ |
9/10 dogs prefer NexGard SPECTRA®
of dogs prefer
NexGard SPECTRA®
to Simparico Trio™1
of dogs prefer
NexGard SPECTRA®
to Credelio™ Plus2
Hear why practices are choosing NexGard SPECTRA®
For more information, read the full vet brochure
NexGard SPECTRA® has a proven safety profile3
- Well tolerated, even in puppies – adverse effects are uncommon and generally transient and self-limiting
- No adverse reactions when overdosed at up to 5x maximum dose
- MDR-1 mutant collies – no treatment-related changes at 5x maximum dose¶
NexGard SPECTRA® for simplicity
Simplifies and rationalises shelf stock
Explore the latest...
Owner materials
Handy resources, like posters for your veterinary practice, and materials to support your client communications.
Puppy campaign
Engage with new puppy owner clients, helping to keep their new family member happy and healthy while building a lifelong connection with your practice.
Introducing Parassess®
A FREE online, easy-to-use parasite risk checker that helps owners to help you assess their dog’s individual risk. Enables a timely, risk-based prescribing decision in your busy practice.
- Owner materials
- Puppy campaign
- Parassess risk checker
Choose NexGard SPECTRA®...
-
For dogs
Learn more -
For owners
Learn more -
For practices
Learn more
*NexGard SPECTRA® also covers heartworm, hookworm, whipworm and eyeworm. NexGard SPECTRA®’s mite indication is for treatment of sarcoptic mange, demodicosis and otodectes cynotis. NexGard SPECTRA® does not cover tapeworms.
†Otodectes cynotis.
‡The safety of the veterinary medicinal product has not been established in breeding males. In breeding males, use only according to the benefit-risk assessment by the responsible veterinarian.
§The table shows activity against fleas, ticks, roundworm, lungworm and mites. Some of the products listed have claims against other parasites. Refer to the Summary of Product Characteristics for each product for full details of the licensed indications.
**9 out of 10 dogs that demonstrated a preference in the studies preferred NexGard SPECTRA®.
‡‡Credelio™ Plus – the safety of product has not been established during pregnancy, lactation or in breeding dogs. Use only according to benefit-risk assessment by the responsible veterinarian.
††Where SPC advises to give with/shortly after food, this is recorded here as X.
§§Credelio™ Plus is licensed to treat demodicosis but not sarcoptic mange or ear mites. Simparica TRIO™ is licensed to treat demodicosis and sarcoptic mange, but not ear mites.
¶The recommended dose should be strictly observed in collies or related breeds.
References:
- Perier N, Carithers DS, Everett WR, et al. Preference of Dogs between Two Oral Formulations of Endectoparasiticides: NexGard SPECTRA® (Afoxolaner and Milbemycin Oxime) and Simparica TrioTM (Sarolaner, Moxidectin and Pyrantel). Open Journal of Veterinary Medicine 2020;10:155–163.
- Perier N, Carithers DS, Everett WR, et al. Preference in Dogs of Two Oral Endectoparasiticide Formulations: NexGard SPECTRA® (Afoxolaner and MilbemycinOxime) and CredelioTM Plus (Lotilaner and Milbemycin Oxime). Open Journal of Veterinary Medicine 2021;11:289–298.
- EMA. European Public Assessment Report (EPAR): NexGard SPECTRA® chewable tablets for dogs (afoxolaner and milbemycin oxime). European Medicines Agency, London.
NexGard SPECTRA® contains afoxolaner and milbemycin oxime. UK: POM-V IE: POM. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical). IE Tel: 01 291 3985 (all queries). Email: vetenquiries@boehringer-ingelheim.com. NexGard SPECTRA® is a registered trademark of Boehringer Ingelheim Animal Health France SCS, used under licence. ©2026 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Feb 2026. UI-PET-0373-2025. Use Medicines Responsibly.
Prescription decisions are for the person issuing the prescription alone.